Our results illustrated the dismal prognosis of GAC patients with high-CD155 along with a decreased level of tumor-infiltrating T/B lymphocytes, indicating that the expression level of CD155 and the infiltration degree of T or B lymphocyte could be a combined indicator for the prognosis of patients, which provides a potential marker for the subsequent treatment with anti-TIGIT antibodies. This evidence concerns the gene TIGIT and neoplasm.